Pier Capital’s Telix Pharmaceuticals TLX Stock Holding History

Pier Capital’s Portfolio TLX Stock Details TLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-188,992	Closed	-$3.04M	–	141
2025 Q2	$3.04M	Buy	+188,992	New	+$3.17M	0.46%	89

Other funds holding TLX

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PIC

Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return

Pier Capital's TLX Position: Q3 2025 in Review

Pier Capital sold out of Telix Pharmaceuticals (TLX) in Q3 2025, closing a stake of 188,992 shares — an estimated $3.04M sold.

Pier Capital first reported a position in TLX in Q2 2025 and held it in 1 quarter. The position peaked at $3.04M in Q2 2025. 27 funds tracked by Wall St. Rank hold TLX as of Q3 2025.

Pier Capital reported no remaining Telix Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Pier Capital sold 188,992 Telix Pharmaceuticals shares in Q3 2025, an estimated $3.04M.
Pier Capital first reported a position in Telix Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Pier Capital's Telix Pharmaceuticals position peaked at $3.04M in Q2 2025.
27 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q3 2025.

Based on Pier Capital's 13F filing for Q3 2025, filed 13 Nov 2025.